🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Min Fang

Zhejiang International Studies University

ORCID: 0000-0001-6688-437X

Also affiliated with Anhui Medical University, Shanghai University of Traditional Chinese Medicine, First Affiliated Hospital of Anhui Medical University, Northern Jiangsu People's Hospital, Shuguang Hospital, Yangzhou University, Agency for Healthcare Research and Quality

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia”.

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia

Haematologica(2022)10.3324/haematol.2022.281585

N/A

0.505DataRank · unranked

28 citations

Jacob A. Wilson, Min Fang, Brenda M. Sandmaier, Eduardo Rodríguez‐Arbolí, Brent L. Wood +4 more

Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia

JCO Oncology Practice(2020)10.1200/jop.19.00133

N/A

0.477DataRank · unranked

23 citations

Megan Othus, Guillermo Garcia‐Manero, Min Fang, Jerald P. Radich, David A. Rizzieri +24 more

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2148212

N/A

0.406DataRank · unranked

14 citations

Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby +15 more

Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients

Biomarker Research(2023)10.1186/s40364-023-00461-0

N/A

0.241DataRank · unranked

4 citations

Xing Hua, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, Harry P. Erba +14 more

406P Neoadjuvant chemo-immunotherapy versus neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Annals of Oncology(2024)10.1016/j.annonc.2024.05.320

N/A

0DataRank · unranked

0 citations

Min Fang, Yue Jiang, K. Tao, Yu Ji, X. Wang

Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function

Cell stem cell(2022)10.1016/j.stem.2022.02.010

N/A

0DataRank · unranked

38 citations

J. Philip Creamer, Sintra Stewart, Massiel Chavez Stolla, Yuchuan Wang, Jing Du +12 more

Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.10.002

N/A

0DataRank · unranked

12 citations

Ajay K. Gopal, Brian G. Till, Mazyar Shadman, Ryan C. Lynch, Andrew J. Cowan +10 more

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7561

N/A

0DataRank · unranked

1 citations

Jonathan R. Fromm, Min Fang, Brian G. Till, Mazyar Shadman, Andrew J. Cowan +11 more